This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lamm, P. Articles by Reichart, B. Search for Related Content PubMed PubMed Citation Articles by Lamm, P. Articles by Reichart, B. Related Collections Transplantation CV surgery: coronary artery disease Endothelium/vascular type/nitric oxide Other Research

(Circulation. 2001;104:I-108.)
© 2001 American Heart Association, Inc.

Surgery for Coronary Artery Disease

Autologous Endothelialized Vein Allograft

A Solution in the Search for Small-Caliber Grafts in Coronary Artery Bypass Graft Operations

Peter Lamm, MD; Gerd Juchem, MD; Stefan Milz, MD; Matthias Schuffenhauer, MD; Bruno Reichart, MD

From the Departments of Cardiac Surgery, Anesthesiology, and Anatomy, Ludwig-Maximilians University of Munich, and from the Department of Medicine (Cardiology), Stiftsklinik Augustinum, Munich.

Correspondence to Peter Lamm, MD, Department of Cardiac Surgery, Herzklinik der Universität München, Wolkerweg 16, 81375 München, Germany. E-mail Lamm{at}lrz.uni-muenchen.de

Background— Early graft failure after the use of less satisfactory autologous grafts (30% of all vein grafts) is caused primarily by the following problems: (1) suitable autologous transplants are limited; (2) biotechnology has not yet been able to produce reliable graft substitutes that are legally and ethically approved; and (3) current prosthetic materials are prothrombotic. To overcome these problems, we developed an easily accessible, quality-controlled graft.

Methods and Results— Human autologous venous endothelial cells (HAVECs) were isolated from short segments of peripheral veins unsuitable for bypass grafting. After mechanical deendothelialization of cryopreserved allograft veins (CAVs) and precoating with recipient autologous serum, these homologous cells were seeded by use of a rotating device. Growth of a confluent HAVEC layer within 1 week in a special incubator was observed. After histological and mechanical tests, 12 patients received 15 grafts in total. Bypass operation was followed by clinical and angiographic follow-up. Production period was 22±8 days. HAVEC-coated CAVs showed normal connective tissue wall structure and a tight endothelial monolayer (burst pressure >2000 mm Hg). To date, 12 CABG patients lacking suitable autologous graft material have been treated. One patient died of a cause unrelated to the grafts, which were found morphologically normal and patent during autopsy. Of 15 grafts, 2 were occluded at the first angiographic follow-up. The oldest graft has now been in place for 3 years. Immune suppression was not administered.

Conclusions— At present, autologous endothelialized CAVs present good alternative small-caliber grafts for patients lacking suitable autologous vessels.

Key Words: endothelium • bypass • coronary disease • transplantation • revascularization